Taxotere (Docetaxel) Eye Injury
The Taxotere (Docetaxel) Eye Injury litigation was centralized before Judge Jane Triche Milazzo in the Eastern District of Louisiana in February 2022, consolidating claims that the chemotherapy drug docetaxel caused excessive tearing, canalicular stenosis, or other lacrimal-duct injuries in patients treated for breast cancer. It is procedurally related to, but legally distinct from, the earlier Taxotere hair-loss MDL before the same judge, since it addresses a different alleged injury mechanism requiring its own causation and damages record.
With 140 of 433 total filed actions still pending, this docket sits in a mid-stage phase: a meaningful share of the original filing population has resolved or been dismissed, but a substantial active population remains, and the case-specific general-causation record for eye injury has not developed to the same extent as the earlier hair-loss theory in the related docket. What drives resolution risk here going forward is largely that causation question — whether and to what degree eye-injury claims can establish a reliable link to docetaxel exposure — together with individualized damages proof tied to the severity and treatment history of each claimant's condition.
The relationship between this docket and its predecessor is a useful structural example of how a single drug and manufacturer can generate multiple, separately centralized MDLs addressing different injury theories, each developing on its own timeline even while sharing a judge and much of the underlying factual record about the drug itself. Criterica Intelligence's platform tracks this kind of related-docket structure across the federal MDL system, distinguishing genuinely separate causation and resolution paths from claims that might appear related on the surface. A companion funding brief for this docket is available through Criterica Capital.
It addresses a distinct alleged injury — lacrimal-duct conditions and excessive tearing — rather than the permanent hair loss at issue in the earlier docket, requiring its own general-causation and damages record even though it involves the same drug and manufacturer.
With 140 of 433 total filed actions still pending, the docket has moved past its initial formation phase and resolved a meaningful share of its original filings, but a substantial active population remains without a mature settlement framework.
Primarily the strength of the eye-injury causation record, which is less developed than the hair-loss theory in the related docket, together with individualized damages proof tied to each claimant's diagnosis and treatment history.
It shows how a single drug can generate multiple, separately centralized MDLs for different injury theories, each on its own resolution timeline even while sharing a judge and underlying factual record — a pattern Criterica Intelligence tracks across the federal MDL system.
Statistics shown reflect historical or illustrative model outputs derived from real case data. They are not predictions or guarantees of any individual outcome. Litigation results depend on facts, jurisdiction, judge, and counsel, and vary case by case. Model accuracy is subject to selection effects and changing legal dynamics.